Xylazine, a non-opiate animal tranquilizer, has emerged as the most prevalent adulterant in illicit drugs and is contributing to overdose deaths. Xylazine is unregulated by the FDA and presents unique challenges to healthcare providers due to its severe psychological and physiological effects. This quality improvement project aimed to enhance clinician preparedness to address xylazine exposure within the Veteran population served by a large metropolitan Veterans Affairs Medical Center in the Northwestern United States.